Coherus Oncology (CHRS) Profit After Tax (QoQ) (2013 - 2026)
Coherus Oncology (CHRS) Profit After Tax (QoQ) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Coherus Oncology | 200.42 Mn | 33.38 Mn | 8.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.82% |
| Dec 31, 2025 | -5.94% |
| Sep 30, 2025 | -111.93% |
| Jun 30, 2025 | 728.23% |
| Mar 31, 2025 | 83.91% |
| Dec 31, 2024 | -2,640.18% |
| Sep 30, 2024 | 16.79% |
| Jun 30, 2024 | -112.56% |
| Mar 31, 2024 | 229.15% |
| Dec 31, 2023 | -100.94% |
| Sep 30, 2023 | 7.53% |
| Jun 30, 2023 | 43.39% |
| Mar 31, 2023 | -28.64% |
| Dec 31, 2022 | 32.06% |
| Sep 30, 2022 | -72.78% |
| Jun 30, 2022 | 47.81% |
| Mar 31, 2022 | -110.13% |
| Dec 31, 2021 | -18.68% |
| Sep 30, 2021 | -28.86% |
| Jun 30, 2021 | 82.71% |